Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02081404 · ClinicalTrials.gov registry record · NA
Diagnosis of Acid Reflux Disease Using Novel Imaging: A Prospective Study
A NA study, sponsored by Midwest Biomedical Research Foundation.
- Completed
- Registry status
- NA
- Development phase
- 98
- Enrollment target
NCT02081404 is a NA study that has completed, run by Midwest Biomedical Research Foundation. The registered enrollment target is 98 participants.
The verdict
NCT02081404, a NA study, has completed, sponsored by Midwest Biomedical Research Foundation.
- COMPLETED
- Registry status
- NA
- Development phase
- 98 participants
- Enrollment target
Study Summary
Gastroesophageal reflux disease (GERD), a common chronic disorder in the veteran population, is associated with drug costs exceeding $ 10 billion/year. Only 30-40% of patients with reflux symptoms have erosive esophagitis. The vast majority suffers from non erosive reflux disease (NERD), a condition in which standard endoscopy fails to identify any mucosal breaks and is unable to confirm the diagnosis. Unfortunately, a gold standard for the diagnosis of NERD does not exist. Narrow band imaging (NBI) utilizes spectral narrow band filters (incorporated into standard endoscopes) and helps to see abnormal areas not identified during standard endoscopy. Preliminary results have shown that NBI endoscopy may represent a significant improvement over standard endoscopy for the diagnosis of NERD. The purpose of this study is to accurately diagnosis non acid reflux disease by using a blue light (also known as NBI)upper endoscopy technique.
Interventions
- DRUG Placebo
- DRUG Esomeprazole
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 98 participants |
| Start Date | 2009-03-01 |
| Est. Completion | 2020-08-05 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02081404
The ClinicalTrials.gov registry entry for NCT02081404 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 98 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Midwest Biomedical Research Foundation, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02081404 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02081404 about?
NCT02081404 is a clinical study titled "Diagnosis of Acid Reflux Disease Using Novel Imaging: A Prospective Study". Gastroesophageal reflux disease (GERD), a common chronic disorder in the veteran population, is associated with drug costs exceeding $ 10 billion/year. Only 30-40% of patients with reflux symptoms have erosive esophagitis. The vast majority suffers from non erosive reflux disease (NERD), a condition...
What is the current status of trial NCT02081404?
This trial is currently completed. It is a NA study. The enrollment target is 98 participants. The study started on 2009-03-01. Estimated completion is 2020-08-05.
What interventions are being tested in trial NCT02081404?
The interventions under investigation include: Placebo (DRUG), Esomeprazole (DRUG).
Who is sponsoring clinical trial NCT02081404?
This trial is sponsored by Midwest Biomedical Research Foundation, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.